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Abstract
Background: In the recent years two innovative approaches have become available for minimally invasive en bloc
resections of large non-pedunculated rectal lesions (polyps and early cancers). One is Transanal Minimally Invasive
Surgery (TAMIS), the other is Endoscopic Submucosal Dissection (ESD). Both techniques are standard of care, but a
direct randomised comparison is lacking. The choice between either of these procedures is dependent on local
expertise or availability rather than evidence-based. The European Society for Endoscopy has recommended that a
comparison between ESD and local surgical resection is needed to guide decision making for the optimal approach
for the removal of large rectal lesions in Western countries. The aim of this study is to directly compare both
procedures in a randomised setting with regard to effectiveness, safety and perceived patient burden.
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Methods: Multicenter randomised trial in 15 hospitals in the Netherlands. Patients with non-pedunculated lesions
> 2 cm, where the bulk of the lesion is below 15 cm from the anal verge, will be randomised between either a
TAMIS or an ESD procedure. Lesions judged to be deeply invasive by an expert panel will be excluded. The primary
endpoint is the cumulative local recurrence rate at follow-up rectoscopy at 12 months. Secondary endpoints are: 1)
Radical (R0-) resection rate; 2) Perceived burden and quality of life; 3) Cost effectiveness at 12 months; 4) Surgical
referral rate at 12 months; 5) Complication rate; 6) Local recurrence rate at 6 months. For this non-inferiority trial, the
total sample size of 198 is based on an expected local recurrence rate of 3% in the ESD group, 6% in the TAMIS
group and considering a difference of less than 6% to be non-inferior.
Discussion: This is the first European randomised controlled trial comparing the effectiveness and safety of TAMIS
and ESD for the en bloc resection of large non-pedunculated rectal lesions. This is important as the detection rate
of these adenomas is expected to further increase with the introduction of colorectal screening programs
throughout Europe. This study will therefore support an optimal use of healthcare resources in the future.
Trial registration: Netherlands Trial Register, NL7083, 06 July 2018.
Keywords: Endoscopic submucosal dissection, Transanal minimally invasive surgery, Rectal cancer, Adenoma
Background
Colorectal cancer (CRC) has the second highest inci-
dence rate of all cancers in Europe with an annual inci-
dence rate of approximately 500.000 of which 175.000
are located in the rectum [1].. Since the introduction of
population based screening, CRCs are more often de-
tected at an earlier disease stage than symptom-detected
CRCs [2]. Resection of pre-malignant precursors has
shown to lower the mortality rate due to CRC by 50%
[3]. Along with the clearly benign polyps and clearly in-
vasive cancers, colorectal cancer screening also detects
many lesions in the act of progressing from one to the
other. These lesions present a diagnostic challenge and
complex clinical decision making to avoid overtreatment
with unnecessary mortality and morbidity on the one
hand but also undertreatment on the other. This di-
lemma is most acute for rectal lesions where standard
surgical resection techniques are associated with higher
rates of mortality and serious morbidity, such as a per-
manent stoma and sexual dysfunction, which can be
avoided by organ sparing techniques [4].
Ideally, preoperative staging would allow for accurate
prediction of invasive cancer and the chance of local
lymph node metastases. Unfortunately, current pre-
operative staging is far from perfect. This is true for all
available staging modalities (MRI, endoscopic ultra-
sound, advanced optical endoscopic imaging) both indi-
vidually and in combination. This has been shown by a
previous randomised study of organ sparing treatment
of rectal polyps, the TREND study: 13% of the lesions
preoperatively staged as benign turned out to be malig-
nant [5]. Currently most lesions that are not overtly can-
cerous on endoscopic inspection are resected by
piecemeal Endoscopic Mucosal Resection (pEMR) in
Western countries. However, piecemeal resection has an
important disadvantage in that it prevents optimal
histological assessment. This can make histological dis-
tinction between a benign and a malignant lesion impos-
sible leading to unnecessary surgical resections or to
under staging and undertreatment. The safety and feasi-
bility of en bloc resections in the rectum, combined with
the limitations of preoperative staging are leading to a
shift away from pEMR to en bloc resection of large le-
sions in the rectum. Furthermore, a recent cost-
effectiveness analysis suggests that an en bloc resection
strategy might also be cheaper than a piecemeal resec-
tion strategy for rectal lesions by reducing the numbers
of patients requiring additional radical rectal surgery [6].
Lesions can be removed en bloc with a flexible endo-
scope by Endoscopic Submucosal Dissection (ESD). ESD
results in high en bloc rates and low recurrence rates of
around 2% [7]. However, ESD has longer procedure
times, is difficult to perform and associated with rela-
tively high rates of perforation (5%) [8]. Fortunately, the
clinical consequences of perforation in the rectum are
usually limited and can almost always be treated conser-
vatively. Several surgical techniques are also available for
local en bloc resection of large non-pedunculated rectal
lesions. Such as Transanal Endoscopic Micosurgery
(TEM) or Transanal Minimally Invasive Surgery (TAMI
S). The TAMIS technique has largely superseded clas-
sical TEM since it requires minimal investment in spe-
cialised equipment. Here the lesion is removed
transanally with the use of a silicon-rubber port and
standard laparoscopic instruments. Compared to ESD it
also has a relatively short learning curve, short proced-
ure times and is financially well compensated.
No reports have been published comparing TAMIS
and ESD directly. Two recently published meta-analysis
comparing TAMIS/TEM to ESD concluded a similar
rate of adverse events, recurrence rate and en bloc resec-
tion rate [9, 10]. Regarding the procedure and
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hospitalization duration both papers came to a different
conclusion. The first concluded that ESD was associated
with shorter procedure times and duration of
hospitalization [10], the second concluded that there was
no difference [9]. However, both meta-analyses largely
included ESD procedures that were conducted in Asian
countries. As a result the findings may not be represen-
tative for the daily practice in the West where the results
of ESD tend to be inferior. The aim of the TRIASSIC
study is to perform a multicentre, randomised controlled
study comparing ESD to TAMIS for the en bloc removal
of large non-pedunculated rectal lesions in a Western
population. This is important as the detection rate of
these lesions has increased greatly with the introduction
of screening programs. This study will enable the opti-
mal use of healthcare resources in the future.
Methods/design
Hypothesis
We hypothesise that ESD will lead to non-inferior recur-
rence rates in lesions that prove to be benign. We hy-
pothesise that TAMIS will have a higher R0 resection
rate for lesions that prove to be invasive but that this
will not translate to a reduced need for additional sur-
gery. We further hypothesise that ESD will lead to less
serious complications than TAMIS and lower societal
costs.
Objective
The primary aim of this study is to compare both proce-
dures with regard to local recurrence rates at 12 months.
The secondary aims are to compare costs, complication
rates and the burden perceived by patients in both the
short and long term between the two procedures.
Design
This will be a multicentre randomised non-inferiority
trial comparing TAMIS and ESD in patients with large
rectal lesions. The flowchart of the design of the TRIA
SSIC study is shown in Fig. 1.
Randomisation
Patient data will be entered into a cloud-based electronic
data capture system (Castor). This system will randomise
patients to either the TAMIS or the ESD group. Stratifi-
cation will take place for the distance of the lesion to the
dentate line and lesion size.
Blinding
Blinding was deemed unfeasible for this trial since both
procedures are very different in nature, performed by
different specialists and require different associated care
facilities within the hospital.
Study population
In order to be eligible to participate in this study, a sub-
ject must meet all of the following inclusion criteria:
1. Non-pedunculated lesion > 2 cm in the rectum
where the bulk of the lesion is below 15 cm from
the anal verge found at endoscopy
2. ≥18 years old
3. Written informed consent
A subject is not eligible for inclusion in case of pres-
ence of any of the following exclusion criteria:
1. Features of advanced disease or deep-submucosal
invasion at optical endoscopic evaluation*
2. Features of advanced disease on cross-sectional
imaging*
3. Prior endoscopic resection attempt
4. The risks of treatment are felt to exceed the
benefits.
* Where there is discordance in the results, the optical
endoscopic evaluation will be given the most weight and
the case discussed by an expert panel.
Participating centres
The TRIASSIC study will be performed in the
Netherlands in at least 5 academic and 10 non-academic
centres. The following hospitals are participating in the
trial: Leiden University Medical Center, Amsterdam Uni-
versity Medical Center (Amsterdam Medical Center and
Vrije Universiteit University Medical Center), University
Medical Center Utrecht, Erasmus medical Center, IJssel-
land hospital, Alrijne hospital, Haaglanden Medical Cen-
ter, Diakonessenhuis, Deventer hospital, Meander
Medical Center and the St. Antonius hospital. The fol-
lowing hospitals have shown interest in participation:
Bravis hospital, Isala hospital, Albert Schweitzer hospital,
Maasstad hospital, Netherlands Cancer institute, Univer-
sity Medical Center Groningen, Maastricht University
Medical Center, Medical Center Leeuwarden, Elisabeth-
TweeSteden hospital, Laurentius hospital, Gelre hospital
and Hagaziekenhuis.
Intervention strategies
Transanal minimally invasive surgery (TAMIS)
This procedure was first described by Atallah et al. [11].
The procedure will be performed under either general
or spinal anaesthesia at the discretion of the anaesthetist.
For this trial only the GelPOINT® path transanal access
platform will be used. This is to ensure the greatest pos-
sible uniformity in procedures and was already being
used by the vast majority of surgeons prior to the study.
After insertion of the instruments the margins of the
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lesion may be marked with coagulation dots to facilitate
the incision at the lesion margins at the discretion of the
surgeon. The incision must be placed at a distance of at
least 5 mm around the border of the lesion to prevent
thermal damage complicating the histological assess-
ment. If a lesion is very distal (i.e., at or just above the
dentate line), the distal margin can be incised using
standard transanal retractors and electrocautery. Before
the start of the lateral or proximal portion of the dissec-
tion, the TAMIS port can be inserted to be used for the
remainder of the dissection. Ideally a partial thickness
resection of the lesion will be performed following the
intramuscular plane of the muscularis propria using a
diathermic hook but a full thickness resection may be
performed at the discretion of the surgeon. The wound
may be closed, if required, with laparoscopic suture ma-
terial in a transverse direction so as not to narrow the
lumen of the rectum. The type of sedation and precise
instruments will be noted in the CRF. Pneumorectum
will be achieved using CO2 for insufflation. Initial pres-
sure settings should be between 12- and 20-mmHg and
can be increased if there is difficulty in maintaining dis-
tension for visualisation. An anal block with bupivacaine
or ropivacaine bilaterally is recommended. All other as-
pects of the procedure and post-procedural care are at
the discretion of the operator.
Fig. 1 Flowchart of the TRIASSIC study. Abbreviations: TAMIS: Transanal Minimally Invasive Surgery, ESD: Endoscopic Submucosal Dissection
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Endoscopic submucosal dissection (ESD)
After insertion of the endoscope the margins of the le-
sion may be marked with coagulation dots to facilitate
the incision at the lesion margins at the discretion of the
endoscopist. The lesion will be ‘lifted’ by injection of
fluid into the submucosa. The choice of injection fluid is
at the discretion of the operator. A partial or full cir-
cumferential incision will be made around the lesion (at
the discretion of the operator) at a distance of at least 5
mm from the border of the lesion to prevent thermal
damage complicating the histological assessment. Dis-
section will take place in the submucosal layer under-
neath the specimen just above and parallel to the
underlying muscularis propria layer. The choice of ESD
knife is at the discretion of the operator and must be re-
corded in the CRF. All procedures will be performed
with a high-resolution magnifying video- endoscope.
The procedure will be performed under sedation, not
general anaesthesia. The choice of sedation technique is
at the discretion of the endoscopist but Propofol sed-
ation is recommended. In the case of intraprocedural
perforation, this will be treated using clips and desuffla-
tion of the peritoneal cavity if required, with an intra-
venous cannula. In the case of minor bleeding from a
small vessel, contact coagulation with the tip of a knife
or coagulation with haemostatic forceps will be used for
haemostasis. In cases of a severe bleeding from a large
vessel or artery, haemostatic forceps will be used for
haemostasis. If a pulsating large vessel is exposed within
the resection wound, clipping can be performed to pre-
vent delayed bleeding. All of this is considered standard
care and should be mentioned in the CRF. All other as-
pects of the procedure and post-procedural care are at
the discretion of the operator.
Decision-making regarding patient management
Patients will be discussed at the local multidisciplinary
meeting (standard care) and decisions regarding the
management of the patient including the need for add-
itional radical surgical resection or other treatment op-
tions, will be made there in the normal way in
accordance with the current national guidelines.
Follow-up
The follow-up consists of a rectoscopy performed 6 and
12months after the TAMIS/ESD by an endoscopist
trained in advanced endoscopic imaging techniques.
Three white light pictures, 3 enchanced imaging pictures
and preferably a short video should be taken of the scar.
In case of no visible recurrence 3 biopsies of the scar
should be taken. In case of visible benign recurrence an
attempt at an endoscopic resection will be performed, or
a re-TAMIS. If recurrence is found at the 12-month
rectoscopy this will be resected and further surveillance
will be planned for 6 months later.
Informed consent procedure
Patients meeting all criteria stated above will be in-
formed about the trial at the outpatient clinic by a mem-
ber of the research team. After written consent is
obtained the patient will be allocated to either the TAMI
S or the ESD group by computerised randomisation.
Subsequently, the patient will be scheduled for therapy
at a participating centre.
Intervention failure: cross-over
If the primary procedure fails, cross-over to the other
treatment is possible, but only if the specialist that has
to perform the cross-over treatment, deems it feasible.
Quality assurance
Expert panel
An expert panel was established for this trial consisting
of five gastroenterologists (JH, JB, LM, AK, BB) and
three surgeons (PD, EG, RH). All are specialized in the
assessment and treatment of advanced polyps and (early
invasive) rectal cancers and perform either the ESD or
the TAMIS procedures within this trial. All lesions
should be approved by the expert panel before random-
isation by review of the endoscopy pictures and video. A
lesion is deemed as suitable for participation if a mini-
mum of 2 gastroenterologists and 1 surgeon think the
lesion meets the criteria. The expert panel can also be
consulted in difficult cases (for example when advanced
cross-sectional imaging and endoscopic assessment
disagree).
Experience requirement
Specialists performing ESD or TAMIS in the TRIASSIC
study need to have performed at least 25 procedures.
The specialists will be asked to send anonymised pro-
cedural data including lesion characteristics, procedure
time, complications, histology and follow up (if available)
of the latest 15 procedures and an unedited video. To be
able to perform procedures in the TRIASSIC study at
least 10 of these 15 procedures must have resulted in a
R0 resection of lesions > 2 cm in size and must have
been performed without complications.
Histopathological evaluation
Appropriate handling of the resected specimens is crit-
ical for accurate histological assessment and will be done
as follows (identical to standard care). The resected spe-
cimen will be pinned onto a paraffin, rubber or cork
sheet so that the normal mucosa surrounding the lesion
is evenly flattened and the mucosal surface can be ob-
served. The specimen will then be photographed with a
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millimetre ruler next to it and fixed in formalin. The
specimen should, preferably, be examined by a GI path-
ologist. The specimen should be photographed, mea-
sured and macroscopic appearance described including
the lesion, mucosal defects, other abnormalities and the
resection margins. The specimen should also be inked.
A different colour should be used for the resection plane
and the edges of defects. A tangent that touches the
focus closes to the horizontal margin is assumed. The
first cut is carried out in the direction perpendicular to
the tangent. Hereafter the specimen is sectioned into
slices parallel to the first cut. Lastly all slices should be
embedded in cassettes for histological diagnosis. Incom-
plete (R1) resection is defined as tumour infiltration of
the margins and/or if infiltration cannot be determined
because of coagulation artefacts. In case of an adenocar-
cinoma the high-risk factors will be assessed; grade of
tumour budding, invasion depth, differentiation grade,
presence of lymphovascular invasion and radicality.
Central pathology revision
All resection specimens will be revised centrally by an
expert pathologist.
Outcomes
Primary study endpoint (for non-inferiority)
1. Cumulative recurrence rate at follow-up rectoscopy
after 12 months, histologically confirmed from
resected visible residual disease or, if not present,
from biopsies of the scar
Secondary study endpoints
2. Radical (R0-) resection rate, defined as dysplasia-
free vertical and lateral resection margins at
histology
3. To compare the perceived burden of the treatment
and quality of life among patients using
questionnaires ((EORTC) QLQ-C29 [12], EUROQOL
EQ-5D-5L [13], COREFO [14]).
4. Overall complication rate*
5. Surgical referral rate defined as the number of
patients that are referred for trans-abdominal surgi-
cal management at 12 months
6. Cost effectiveness at 12 months.
* complications are defined as follows
 Intraprocedural peritoneal breach: the condition in
which the abdominal cavity is visible from the
colorectal lumen during the procedure because of
mural tissue defects, that requires (1) (prolonged)
admission or (2) surgery
 Intraprocedural bleeding: bleeding that occurs during
the procedure that cannot be controlled by standard
local haemostasis techniques such as
electrocoagulation or clips and that requires (1)
transfusion or (2) termination of the TAMIS or ESD
procedure.
 Postprocedural bleeding: bleeding within 30 days
after the procedure resulting in (1) new presentation
at the hospital, (2) hospital admission, transfusion
(3) or (4) repeated intervention to obtain
haemostasis.
 Postprocedural bowel perforation: a bowel
perforation within 30 days after the procedure that is
detected after completion of the procedure during
which a peritoneal breach did not occur, diagnosed
by abdominal pain with focal guarding and a rise in
C-reactive protein and/or fever (T > 38.5 C) in com-
bination with free air in the peritoneal cavity at ab-
dominal CT.
 Postprocedural serositis: abdominal pain with focal
guarding and/or fever (T > 38.5 C) within 30 days
after the procedure, but without signs of perforation
(free air at abdominal CT) and in the absence of
another infection focus (urinary, pulmonary etcetera)
that requires (prolonged) admission
Sample size calculation
The sample size was calculated for the primary out-
come parameter, the cumulative recurrence rate at 12
months. To assess the non-inferiority of the ESD pro-
cedure the sample size calculation was based on the
assumption that the recurrence rate will be 3% in the
ESD group and 6% in the TAMIS group based on a
systematic review of the literature specifically for
studies performed in the West. If there is a true dif-
ference in favour of ESD of 3%, then 166 patients are
required to be 80% sure that the upper limit of a
one-sided 97.5% confidence interval (or equivalently a
95% two-sided confidence interval) will exclude a dif-
ference in favour of the TAMIS of more than 6%.
(Software: PASS Version 15 – www.ncss.com). We
have chosen a non-inferiority margin of 6% because
we believe that this difference in risk of benign recur-
rence between the intervention group and usual care
group is clinically acceptable. To allow for patients
lost to follow-up (4%) and patients requiring add-
itional surgical resection due to high risk characteris-
tics (12%) in whom the primary outcome cannot be
assessed, a total of 198 patients will be included; 99
patients in each arm. The incidence of large rectal
non-pedunculated lesions in the Netherlands is esti-
mated to be between 250 and 500 new cases a year.
We estimated that the participation of 15 centres will
be required to complete the inclusion period within
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3 years. To avoid unnecessary delay, we will start this
trial with 5 centres and will extend the number of
centres during the course of the trial.
Ethics
This clinical investigation will be conducted in ac-
cordance with the ethical principles that have their
origin in the Declaration of Helsinki. This clinical in-
vestigation will comply with the practices set out in
EN ISO14155:2011. This investigation was approved
by the Medical Ethics Committee of the Leiden Uni-
versity Medical Center (NL61603.058.18). The study
will be conducted according to the rules on medical
research involving human subjects (Medical Research
(Human Subjects) Act), in Dutch: Wet Medisch-
Wetenschappelijk Onderzoek met mensen (WMO). In
addition, approval has been obtained from all of the
participating hospitals: Amsterdam University Medical
Center (Amsterdam Medical Center and Vrije Univer-
siteit University Medical Center), University Medical
Center Utrecht, Erasmus medical Center, IJsselland
hospital, Alrijne hospital, Haaglanden Medical Center,
Diakonessenhuis, Deventer hospital, Meander Medical
Center and the St. Antonius hospital.
Data-analysis
To assess the non-inferiority of the ESD procedure, the
difference between the cumulative recurrence rates at
12 months in both groups will be compared to the non-
inferiority margin of 3% using a one-sided Mantel-
Haenszel test (with alpha 0.025) to account for stratifica-
tion factors. For the other variables, normality will firstly
be assessed. The secondary endpoints will be compared
using the student t-test or Mann-Whitney U test and
Chi-square or Fisher’s exact test as appropriate.
Multivariate regression will be considered for adjustment
for possible confounding if necessary. The analysis will
primarily be carried out on an intention-to-treat basis.
Economic evaluation
The Health Economic Expert responsible for the
study will perform the Economic Evaluation. The eco-
nomic evaluation will consist of a cost-effectiveness
analysis from a healthcare perspective (CEA: costs per
prevented recurrence) and a cost-utility analysis from
a societal perspective (CUA: costs per QALY, esti-
mated using the Dutch tariff for the EuroQol EQ-5D-
5L at 0, 6 and 12 months). Both analyses will be trial-
based, using patient reports, with a one-year time
horizon. Costs will include the index interventions
with hospitalisation (estimated from patient charts),
subsequent hospital and non-hospital healthcare and
productivity during the study follow-up (measured
using patient questionnaires at 6 and 12 months).
Cost-price analyses will be performed for the TAMIS
and ESD procedures, including procedure time, mate-
rials and anaesthesia. Other healthcare and societal
costs will be valued and discounted according to the
Dutch guidelines for economic evaluations [15, 16].
Average costs and patient outcome will be compared
according to intention-to-treat, using net-benefit ana-
lysis, and using multiple imputation to account for
missing data.
Discussion
In 2010 The European Union published recommenda-
tions that colorectal cancer screening should be per-
formed in all member states [17]. CRC screening
reveals more large precursor lesions for which local
excision may be the optimal treatment. However, the
choice as to whether to perform local excision and
with which technique is still unclear, especially in
Western countries where Endoscopic Submucosal Dis-
section is being introduced slowly and remains con-
troversial. As stated in the introduction, most lesions
that are not overtly cancerous on endoscopic inspec-
tion are resected by pEMR in Western countries. The
limitations of this technique which only allows sub-
optimal histological assessment are illustrated by the
TREND study; 3 out of 87 (3%) patients had a carcin-
oma during follow-up after removal of a pT0 lesion
in the piecemeal EMR group, versus none in the en
bloc TEM group [5]. Malignant recurrence at the re-
moval site of a benign adenoma occurs in approxi-
mately 1–2% of cases [18, 19]. A possible explanation
is pathological under staging with small areas of inva-
sion being missed in the assessment of the pEMR
specimens. A different explanation is remnant aden-
omatous tissue that progresses into a carcinoma. Sur-
gical resection due to uncertain histology after pEMR
of large lesions optically staged as benign occurs in
3.5% of cases [20]. These limitations are encouraging
a shift away from pEMR towards en bloc resections of
large rectal lesions.
However, the en bloc resection method of choice is
unclear. In 2017 the European Society for Endoscopy
recommended that a comparison between ESD and
local surgical resection is needed to guide decision
making for the optimal approach for the removal of
large rectal lesions in Western countries [21]. The
reason ESD is compared to TAMIS, instead of TEM,
in the TRIASSIC study is because TAMIS provides
the benefits of advanced videoscopic transanal exci-
sion at a fraction of the cost of TEM [11]. No add-
itional investment is required and the TAMIS port
has a shorter shaft length, allowing an increased
working angle and more distal dissection compared to
the TEM port [22]. There are also suggestions that
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TAMIS may be less traumatic to the anal sphincter,
compared to TEM [23].
For this trial it was decided to include all rectal le-
sions > 2 cm, both including those clinically staged as
benign and early invasive. It could be argued that the
advantages of en bloc resection only outweigh the dis-
advantages in early invasive lesions. This is the basis
for the Japanese indications for colorectal ESD where
a lesion must have at least one high risk feature for
early invasion. However, for reasons that are unclear,
Western centres seem to be less good at recognising
these high risk features with very high rates of “cov-
ert” cancer in lesions clinically staged as benign [24,
25]. The likelihood of “covert” cancer is associated
with lesion size, site within the colon and lesion
morphology. In the rectum all clinically benign le-
sions > 2 cm have a > 5% chance of harbouring a focus
of “covert” cancer, regardless of morphology. Piece-
meal EMR is therefore an inappropriate treatment in
at least 5% of rectal lesions > 2 cm. We feel that this
is unacceptably high and that en bloc resection is jus-
tified in all rectal lesions > 2 cm.
Similarly, clinical staging of massive invasion (>T1
sm1) is also only accurate in 50% in expert Western
centres [25]. In the other 50% local en bloc resection
would have been sufficient. Cross sectional imaging
with MRI or Endoscopic Ultrasound does not im-
prove this [26]. Likewise, determination of the N-
status of rectal lesions is problematic. MRI has been
shown to have a sensitivity of 94% and a specificity of
only 67% [27]. A systematic review of the perform-
ance of Endoscopic Ultrasound (EUS) showed a
pooled sensitivity of 73.2% and a pooled specificity of
75.8% [28]. The consequence of the poor performance
of the preoperative staging methods is that the sta-
ging of early stage cancers is increasingly being per-
formed by the histology sample obtained by
diagnostic en bloc resection. This approach has
already been formalized for other early GI cancers
such as oesophageal cancers [29] but not yet for rectal
cancer. Diagnostic resection allows accurate patho-
logical examination but only if performed en bloc and
when care is taken to ensure optimal orientation of
the specimen.
The TRIASSIC study is the first direct comparison be-
tween rectal en bloc resection techniques in a rando-
mised setting in a Western population. The TRIASSIC
study will increase the current knowledge as to which is
the preferred minimally invasive resection method for
rectal en bloc resections. This is important as the detec-
tion rate of large rectal lesions (polyps and early cancers)
has greatly increased with the introduction of CRC
screening. This study will support the optimal use of
healthcare resources in the future.
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